Krishnan Chandra Kumar, Han Ilkyu, Kim Han-Soo
Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.; Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, India.
Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.
Clin Orthop Surg. 2017 Mar;9(1):116-125. doi: 10.4055/cios.2017.9.1.116. Epub 2017 Feb 13.
The pelvic bone is the most common site of bone metastases following the axial skeleton. Surgery on the pelvic bone is a demanding procedure. Few studies have been published on the surgical outcomes of metastasis to the pelvic bone with only small numbers of patients involved. This study sought to analyze the complications, local progression and survival after surgery for metastasis to the pelvic bone on a larger cohort of patients.
We analyzed 83 patients who underwent surgery for metastases to the pelvic bone between the years 2000 and 2015. There were 41 men and 42 women with a mean age of 55 years. Possible factors that might be associated with complications, local progression and survival were investigated with regard to patient demographics and disease-related and treatment-related variables.
The overall complication rate was 16% (13/83). Advanced age (> 55 years, = 0.034) and low preoperative serum albumin levels (≤ 39 g/L, = 0.001) were associated with increased complication rates. In patients with periacetabular disease, the complication rate was higher in those who underwent total hip replacement arthroplasty (THR) than those who did not ( = 0.030). Local progression rate was 46% (37/83). The overall median time to local progression was 26 ± 14.3 months. The median time from local progression to death was 13 months (range, 0 to 81 months). The local progression-free survival was 52.6% ± 6.4% at 2 years and 36.4%± 7.6% at 5 years, respectively. Presence of skip lesions ( = 0.017) and presence of visceral metastasis ( = 0.027) were found to be significantly associated with local progression. The median survival of all patients was 24 months. The 2-year and 3-year survival rates were 52.5% ± 5.9% and 35.6% ± 6%, respectively. Metastasis from the kidney, breast, or thyroid or of hematolymphoid origin ( = 0.014), absence of visceral metastasis ( = 0.017) and higher preoperative serum albumin levels ( = 0.009) were associated with a prolonged survival.
Advanced age and low serum albumin levels were associated with high complication rates. Local progression after surgery for metastases to the pelvic bone was affected by the presence of skip lesions, not by surgical margins. Primary cancer type, serum albumin level and visceral metastasis influenced survival.
骨盆是继中轴骨骼之后骨转移最常见的部位。骨盆手术是一项要求很高的手术。关于骨盆骨转移手术结果的研究发表较少,且涉及患者数量不多。本研究旨在分析更大队列的骨盆骨转移患者手术后的并发症、局部进展和生存率。
我们分析了2000年至2015年间接受骨盆骨转移手术的83例患者。其中男性41例,女性42例,平均年龄55岁。就患者人口统计学以及疾病相关和治疗相关变量,研究了可能与并发症、局部进展和生存相关的因素。
总体并发症发生率为16%(13/83)。高龄(>55岁,P = 0.034)和术前血清白蛋白水平低(≤39 g/L,P = 0.001)与并发症发生率增加相关。在髋臼周围疾病患者中,接受全髋关节置换术(THR)的患者并发症发生率高于未接受者(P = 0.030)。局部进展率为46%(37/83)。局部进展的总体中位时间为26±14.3个月。从局部进展到死亡的中位时间为13个月(范围0至81个月)。2年和5年的无局部进展生存率分别为52.6%±6.4%和36.4%±7.6%。跳跃性病变的存在(P = 0.017)和内脏转移的存在(P = 0.027)与局部进展显著相关。所有患者的中位生存期为24个月。2年和3年生存率分别为52.5%±5.9%和35.6%±6%。肾、乳腺或甲状腺转移或血液淋巴源性转移(P = 0.014)、无内脏转移(P = 0.017)和术前血清白蛋白水平较高(P = 0.009)与生存期延长相关。
高龄和低血清白蛋白水平与高并发症发生率相关。骨盆骨转移手术后的局部进展受跳跃性病变的存在影响,而非手术切缘。原发癌类型、血清白蛋白水平和内脏转移影响生存。